The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 6 of the 34 sources its claims cite were checked for support.
Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP
Open accessAbstract
The sterol regulatory element-binding protein (SREBP) transcription factor family is a critical regulator of lipid and sterol homeostasis in eukaryotes. In mammals, SREBPs are highly active in the fed state to promote the expression of lipogenic and cholesterogenic genes and facilitate fat storage. During fasting, SREBP-dependent lipid/cholesterol synthesis is rapidly diminished in the mouse liver; however, the mechanism has remained incompletely understood. Moreover, the evolutionary conservation of fasting regulation of SREBP-dependent programs of gene expression and control of lipid homeostasis has been unclear. We demonstrate here a conserved role for orthologs of the NAD+-dependent deacetylase SIRT1 in metazoans in down-regulation of SREBP orthologs during fasting, resulting in inhibition of lipid synthesis and fat storage. Our data reveal that SIRT1 can directly deacetylate SREBP, and modulation of SIRT1 activity results in changes in SREBP ubiquitination, protein stability, and target gene expression. In addition, chemical activators of SIRT1 inhibit SREBP target gene expression in vitro and in vivo, correlating with decreased hepatic lipid and cholesterol levels and attenuated liver steatosis in diet-induced and genetically obese mice. We conclude that SIRT1 orthologs play a critical role in controlling SREBP-dependent gene regulation governing lipid/cholesterol homeostasis in metazoans in response to fasting cues. These findings may have important biomedical implications for the treatment of metabolic disorders associated with aberrant lipid/cholesterol homeostasis, including metabolic syndrome and atherosclerosis.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
SIRT1 orthologs are required for fasting-dependent down-regulation of SREBP and its lipogenic/cholesterogenic target genes across metazoans. SIRT1 directly deacetylates SREBP, promoting its ubiquitination and turnover, and SIRT1 activators reduce SREBP target expression and hepatosteatosis in obese mice.
Key findings
- In *C. elegans*, fasting decreases intestinal lipids and triglycerides in wild-type animals, but not in *sir-2.1*-null animals; *sir-2.1* loss also prevents fasting-dependent down-regulation of SBP-1 target genes such as *fat-7* and *lbp-6*, while *sir-2.1* overexpression lowers fat storage and target gene expression.
- In *Drosophila*, larvae homozygous for a *dSir2* deletion show increased transcription of dSREBP target genes encoding acetyl-CoA synthase, acetyl-CoA carboxylase, and fatty acid synthase, especially during fasting.
- In mouse liver, SIRT1 shRNA knockdown reduces fasting-dependent down-regulation of FASN, ELOVL6, and SREBP-1c; SIRT1 liver-specific knockout livers show broad up-regulation of SREBP-1 and SREBP-2 targets, including lipogenic and cholesterol biosynthesis genes.
- SIRT1 directly deacetylates SREBP-1a in an NAD+-dependent manner; nicotinamide increases SREBP-1a half-life from ~1 h to ~6 h, and SRT2183 increases SREBP-1a ubiquitination and decreases nuclear SREBP-1. In *ob/ob* mice on high-fat diet, SRT1720 (100 mg/kg daily for 2 or 4 wk) lowers hepatic FASN and SREBP-1c expression at 4 wk and improves hepatosteatosis.
Methods
- Conserved invertebrate assays used *C. elegans* fasting, Sudan Black lipid staining, thin-layer/gas chromatography for triglycerides, qRT-PCR, *sbp-1* RNAi, and GFP reporters for *fat-7* and SBP-1; *Drosophila* Sir2-null third instar larvae were fasted for 24 h and analyzed by qRT-PCR.
- Mammalian experiments used SIRT1 shRNA adenovirus in mouse liver, SIRT1 liver-specific knockout mice, SIRT1 knockout MEFs, human cell lines (HeLa, HEK293T, IMR-90), immunoprecipitation/immunoblotting, immunofluorescence, in vitro deacetylation assays with GST-SIRT1, cycloheximide stability assays, and microarray analysis of SIRT1 LKO livers.
- In vivo SIRT1 activator studies used 6-wk-old *ob/ob* mice fed a high-fat diet, acclimated 2 wk, then dosed with SRT1720 (100 mg/kg) or vehicle by oral gavage daily for 2 or 4 wk (n = 5 per group), with liver lipid extraction and qRT-PCR.
Limitations
- The paper does not include a dedicated limitations section. It notes that the precise mechanistic details of how SIRT1 activators function are still debated (citing Ledford 2008; Pacholec et al. 2010), and that sirtuins may affect multiple metabolic processes, so down-regulation of SREBP activity is described as “a significant contributor” rather than the sole cause of decreased stored lipids.
- The text acknowledges that effects of SIRT1 manipulations could be indirect through CBP/p300, though it reports that immunopurified p300 from SRT2183-treated cells did not show decreased histone acetylation activity.
- It states that it is presently unclear whether AMPK also regulates SREBP in lower metazoans, and that deacetylation may play a minor role in SREBP turnover in nonfasted situations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 of 34 cited sources checked · 1 supported · 0 flagged · accuracy not yet measured
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our data reveal that SIRT1 can directly deacetylate SREBP, and modulation of SIRT1 activity results in changes in SREBP ubiquitination, protein stability, and target gene expression.”
- Also stated in: § SIRT1 directly deacetylates SREBP and controls SREBP protein stability · plain
“wildtype SIRT1 deacetylates SREBP-1a in an NAD + -dependent manner, whereas the catalytically inactive mutant SIR-T1(H363Y) does not (Fig. 5D).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § SIRT1 directly deacetylates SREBP and controls SREBP protein stability · plain
In the paper
“We also found that the SREBP-1c gene itself is significantly repressed in response to SRT1720 treatment for 4 wk in these mice, consistent with the fact that SREBP-1c controls its own expression (Fig. 7E; Amemiya-Kudo et al. 2000).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > SIRT1 activators promote inhibition of SREBP target genes, increased SREBP ubiquitination, and decreased SREBP protein stability, and ameliorate aberrant lipogenesis in vivo
What the sources say
- Not checked — no full text of the sourcecites Amemiya-Kudo et al. 2000 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the expression of several NHR-49 target genes (e.g., cpt-4) is unaffected by sir-2.1 deletion during either feeding or fasting (Fig. 2C; data not shown).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Results
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“overexpression of wild-type SIRT1 causes strong repression of SREBP target genes in human cells (Fig. 4D).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Mammalian SIRT1 represses SREBP-1 and SREBP-2 target gene expression
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that nicotinamide, sirtinol, and siRNA-mediated ablation of SIRT1 all increased the nuclear abundance of SREBP-1a and SREBP-2 in primary human fibroblasts (IMR-90) and cancer cells (HeLa S) (Fig. 6A,B; Supplemental Figs. 7, 8).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Sirtuin inhibition results in increased nuclear SREBP levels
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: Nuclear abundance of SREBP isoforms reflects their functional activity.
- Rests on an assumption: RNAi-mediated SIRT1 ablation is specific for SIRT1.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“nematodes null for the SIRT1 ortholog sir-2.1 exhibit high levels of lipids under both fed and fasted conditions (Fig. 1A; Supplemental Fig. 1A)”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Results
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fasting-dependent decreases in expression of endogenous fat-7 do not occur in sir-2.1(lof)animals.”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > p300 HAT assays
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nicotinamide treatment caused a significant increase in acetylation of both overexpressed and endogenous mature forms of SREBPs, consistent with sirtuin regulation of the SREBP acetylation state (Fig. 5A-C).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > SIRT1 directly deacetylates SREBP and controls SREBP protein stability
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“immunopurified p300 from cells treated with SRT2183 does not exhibit decreased activity in terms of acetylation of histones, suggesting that impaired CBP/p300 activity is unlikely to provide an explanation for the observed effects on SREBPs and their target genes (Supplemental Fig. 8).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > SIRT1 activators promote inhibition of SREBP target genes, increased SREBP ubiquitination, and decreased SREBP protein stability, and ameliorate aberrant lipogenesis in vivo
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The SBP-1 target gene lbp-6 is abnormally regulated in the fasting response of sir-2.1(lof)animals.”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > p300 HAT assays
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- Probably not a substantial claim. 16
- It may state two separate claims as one. 26
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SIRT1 orthologs not only remove acetyl groups from histone tails, they can also deacetylate transcription factors such as p53, NF-kB, and E2F (Haigis and Guarente 2006;Saunders and Verdin 2007;Feige and Auwerx 2008).”
What the sources say
- Partly supportedcites Haigis and Guarente 2006 sourceExperimental — accuracy not yet measured
The ‘SIRT1 substrates in mammals’ section states that SIRT1 deacetylates p53 and NF-κB. The ‘SIRT2’ section also says SIRT1 deacetylates histone H4K16. No passage found in our copy says it deacetylates E2F, so that example is unsupported by this source. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites Saunders and Verdin 2007 source
- Not matchedcites Feige and Auwerx 2008
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SIRT1 protein levels are elevated in the livers of fasted mice and decrease with refeeding (Rodgers and Puigserver 2007), a regulatory pattern converse to that of SREBPs.”
What the sources say
- Partly supportedcites Rodgers and Puigserver 2007 sourceExperimental — accuracy not yet measured
The Discussion (p. 5) reports that SIRT1 protein is induced by fasting in mouse liver, supporting the first part of the claim. Our copy does not state that liver SIRT1 protein decreases with refeeding; fed-versus-fasted results elsewhere concern SIRT1’s effects, not that protein-level change. (LLM, conf=0.86)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“knockdown or knockout of SIRT1 in the mouse liver or transgenic overexpression of SIRT1 in mice results in altered lipid/cholesterol levels in serum and the liver (Li et al. 2007;Rodgers and Puigserver 2007;Pfluger et al. 2008;Erion et al. 2009;Purushotham et al. 2009).”
What the sources say
- Not matchedcites Li et al. 2007
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites Rodgers and Puigserver 2007 sourceExperimental — accuracy not yet measured
The Results (p. 3) show that hepatic SIRT1 knockdown and overexpression altered serum and liver cholesterol, and that knockdown increased liver free fatty acids. However, this paper used shRNA knockdown and adenoviral overexpression, not knockout or transgenic overexpression; it also found no significant change in serum triglycerides or free fatty acids. (LLM, conf=0.88)
- Partly supportedcites Pfluger et al. 2008 sourceExperimental — accuracy not yet measured
The Results report that Sirt1-transgenic mice had substantially less hepatic lipid accumulation than wild-type mice after 19 weeks on a high-fat diet. But plasma cholesterol and triglyceride levels did not differ between genotypes, and this paper does not report a liver-specific Sirt1 knockdown or knockout lipid result. Thus it supports the hepatic-lipid finding for overexpression, not the full claim attributed to it. (LLM, conf=0.90)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Finally, we show that recently developed SIRT1 activators, which are effective in improving energy homeostasis and decreasing hepatosteatosis in mouse models (Milne et al. 2007;Feige et al. 2008), also increase ubiquitination and proteasomal targeting of SREBP-1a, resulting in decreased SREBP-1 nuclear levels and target gene expression.”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Discussion
What the sources say
- Partly supportedcites Milne et al. 2007 sourceExperimental — accuracy not yet measured
The Abstract reports that recently developed SIRT1 activators improved glucose homeostasis and insulin sensitivity in obese mouse models, supporting the metabolic part of the cited parenthetical. Our copy does not report decreased hepatosteatosis. The subsequent SREBP-1a finding is introduced as the citing authors’ own result, not a finding attributed to Milne et al. (LLM, conf=0.86)
- Not matchedcites Feige et al. 2008
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Changes in SREBP target gene expression reflect changes in SREBP transcriptional activity.
- Rests on an assumption: Nuclear abundance of SREBP isoforms reflects their functional activity.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The SREBP ortholog in C. elegans, SBP-1, is necessary for lipid production and for expression of multiple lipogenic genes (McKay et al. 2003;Yang et al. 2006).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Results
What the sources say
- Supportedcites McKay et al. 2003 source
In “SREBP Deletion Mutants Do Not Contain Fat” (page unavailable), loss of the worm SREBP homolog produced worms lacking fat. In “Worm SREBP and C/EBP Regulate Lipogenic Gene Expression” (page unavailable), reducing its function decreased expression of five lipogenic enzymes. The paper uses the name lpd-1 for the SREBP homolog rather than SBP-1, but supports the claim's substance. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites Yang et al. 2006 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“modulation of SIRT1 activity results in changes in SREBP ubiquitination, protein stability, and target gene expression.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Chemical activators of SIRT1 inhibit SREBP target gene expression in vitro and in vivo, correlating with decreased hepatic lipid and cholesterol levels and attenuated liver steatosis in dietinduced and genetically obese mice.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the expression of lipid-binding protein 6 (lbp-6, a novel SBP-1 target gene) (AK Walker and AM Na ¨a ¨r, unpubl.), is also down-regulated by fasting in wild-type animals, but not in sir-2.1 loss-of-function (lof) animals (Fig. 1F).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“nicotinamide treatment of normal human fibroblasts (IMR-90) resulted in increased levels of endoge-nous, mature (nuclear) SREBP-1 and SREBP-2 proteins, while levels of the SREBP-1 and SREBP-2 precursor proteins were unaffected (Fig. 5G, H).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > SIRT1 directly deacetylates SREBP and controls SREBP protein stability
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the SIR-2.1OEstrain exhibits decreased transcription of fat-7 and lbp-6 under both fed and fasted conditions, and has markedly lower intestinal lipid storage as compared with control animals (Fig. 1G,H; Supplemental Fig. 1B; data not shown).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“nuclear SBP-1TGFP expression remains high in fasted nematodes carrying a deletion in sir-2.1, or in animals treated with the sirtuin inhibitors nicotinamide and sirtinol (Fig. 2D; Supplemental Fig. 4A; data not shown).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Results
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thin-layer chromatography and gas chromatography analyses confirmed that total levels of triglycerides decrease during fasting in wild-type animals, but not in sir-2.1-nullanimals (Fig. 1B).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Results
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, SRT2183 treatment decreased the levels of endogenous mature, nuclear SREBP-1 in cultured cells, but had no effect on the SREBP-1 precursor (Fig. 7B,C).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > SIRT1 activators promote inhibition of SREBP target genes, increased SREBP ubiquitination, and decreased SREBP protein stability, and ameliorate aberrant lipogenesis in vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment of nematodes with the sirtuin inhibitors nicotinamide and sirtinol results in markedly increased expression of the fat-7pTGFP reporter in the intestine under fasting conditions, while intestinal GFP expression driven by the elt-2 promoter was unaffected by these treatments, revealing a gene-selective effect of the sirtuin inhibitors (Fig. 1D).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“wildtype SIRT1 deacetylates SREBP-1a in an NAD + -dependent manner, whereas the catalytically inactive mutant SIR-T1(H363Y) does not (Fig. 5D).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > SIRT1 directly deacetylates SREBP and controls SREBP protein stability
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Using animals harboring a hypomorphic allele of sbp-1 [sbp-1(ep79)], we also show that SBP-1 is required for the expression of endogenous fat-7 in fed and fasted animals, and that the accumulation of lipids in fasted sir-2.1-nullanimals is dependent on SBP-1 (Fig. 2B; Supplemental Fig. 2A,B).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This resulted in a nonredundant list of 8573 genes.”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Microarray experiment and data analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Raw intensity values of 389,307 features were subjected to t-test (P < 0.05, two-tail) to extract 13,258 features whose expression significantly differed between the SIRT1 knockout and control animals.”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Microarray experiment and data analysis
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Sudan Black staining reveals that fat storage is decreased in wild-type animals upon fasting, but is maintained in fasted sir-2.1(lof)animals.”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > p300 HAT assays
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Nematodes expressing a SBP-1TGFP fusion protein driven by the sbp-1 promoter exhibit strong nuclear fluorescence in the intestinal cells of fed animals, whereas fasted animals show markedly reduced nuclear SBP-1TGFP levels, consistent with previously published results in mammals (Fig. 2D; Horton et al. 1998).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Results
What the sources say
- Not checked yetcites Horton et al. 1998 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast with fat-7 expression, mRNA expression of sbp-1 or the NHR-49 target cpt-4 was very modestly altered in sir-2.1(lof)animals.”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > p300 HAT assays
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In cholesterol auxotroph invertebrates such as Caenorhabditis elegans and Drosophila melanogaster, SREBP homologs appear to primarily regulate fatty acid/lipid homeostasis (Rawson 2003;Osborne and Espenshade 2009).”
What the sources say
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We demonstrate here a conserved role for orthologs of the NAD + -dependent deacetylase SIRT1 in metazoans in down-regulation of SREBP orthologs during fasting, resulting in inhibition of lipid synthesis and fat storage.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“SREBP family members are controlled in a classic negative feedback manner by the downstream products of the metabolic pathways regulated by SREBPs, such as cholesterol/lipids (Brown and Goldstein 1997;Osborne and Espenshade 2009).”
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In mammals, SREBPs are highly active in the fed state to promote the expression of lipogenic and cholesterogenic genes and facilitate fat storage.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
In the paper
“The mature nuclear forms of SREBP-1 and SREBP-2 are abundant in the mouse liver during feeding, and the expression of fatty acid and cholesterol biosynthesis genes is high, whereas, during fasting, SREBPs are markedly down-regulated, correlating with decreased lipogenic and cholesterogenic gene expression (Horton et al. 1998).”
What the sources say
- Not checked yetcites Horton et al. 1998 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The sterol regulatory element-binding protein (SREBP) transcription factors represent a highly conserved family of gene regulators controlling key genes involved in the biosynthesis and trafficking of lipids and sterols in eukaryotes from Schizosaccharomyces pombe to humans (Osborne and Espenshade 2009).”
What the sources say
- Not checked yetcites Osborne and Espenshade 2009 source
Checked before — its earlier verdict is held back until a new check runs.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Not checked yet
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“More than 30 images from each genotype were scored blind for level of staining in multiple independent experiments.”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > C. elegans
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Recent studies have reported the identification of potent SIRT1-activating compounds, and showed that such SIRT1 activators could significantly ameliorate insulin resistance and improve energy homeostasis in mouse diet-induced obesity models (Milne et al. 2007).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > SIRT1 activators promote inhibition of SREBP target genes, increased SREBP ubiquitination, and decreased SREBP protein stability, and ameliorate aberrant lipogenesis in vivo
What the sources say
- Not checked yetcites Milne et al. 2007 source
Checked before — its earlier verdict is held back until a new check runs.
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not checked yet
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our work shows that the SIRT1 activator SRT2183 impinges on transcriptional programs governing de novo cholesterol/ lipid biosynthesis in cultured cells by rendering SREBP susceptible to ubiquitination; the resulting proteasomal processing decreases the pool of active SREBP, and, consequently, SREBP-dependent gene expression (Fig. 7A-D).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Changes in SREBP target gene expression reflect changes in SREBP transcriptional activity.
- Rests on an assumption: Nuclear abundance of SREBP isoforms reflects their functional activity.
None of the sources cited for this claim have been checked yet.
In the paper
“Indeed, SIRT1 has a well-documented role in stimulation of lipid breakdown in multiple tissues and through several distinct pathways (Yu and Auwerx 2009).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Discussion
What the sources say
- Not checked yetcites Yu and Auwerx 2009 source
Checked before — its earlier verdict is held back until a new check runs.
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not checked yet
None of the sources cited for this claim have been checked yet.
In the paper
“CBP/p300 have been reported to be regulated by sirtuins, including SIRT1 and SIRT2 (Liu et al. 2008), and the effects of SIRT1 manipulations that we observe could therefore be indirect.”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > SIRT1 activators promote inhibition of SREBP target genes, increased SREBP ubiquitination, and decreased SREBP protein stability, and ameliorate aberrant lipogenesis in vivo
What the sources say
- Not checked yetcites Liu et al. 2008 source
Checked before — its earlier verdict is held back until a new check runs.
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not checked yet
None of the sources cited for this claim have been checked yet.
In the paper
“For example, SIRT1 activators increase SIRT1-dependent activation of PGC-1a, FOXO1, and p53, promoting the expression of fatty acid b-oxidation genes (Feige et al. 2008;Smith et al. 2009).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Discussion
What the sources say
- Not matchedcites Feige et al. 2008
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked yetcites Smith et al. 2009 source
Checked before — its earlier verdict is held back until a new check runs.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The absence of systemic bias among samples was confirmed by the box plot analysis supported by the R statistical programming language.”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Microarray experiment and data analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“consistent with the fact that SREBP-1c controls its own expression (Fig. 7E; Amemiya-Kudo et al. 2000).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > SIRT1 activators promote inhibition of SREBP target genes, increased SREBP ubiquitination, and decreased SREBP protein stability, and ameliorate aberrant lipogenesis in vivo
What the sources say
- Not checked — no full text of the sourcecites Amemiya-Kudo et al. 2000 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Cells for photography were selected at random by DAPI staining, and three independent fields were photographed.”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Immunoprecipitation, immunoblotting, and immunofluorescence
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Collectively, these results suggest that SIRT1 can control the stability of mature, nuclear SREBPs by direct deacetylation.”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > SIRT1 directly deacetylates SREBP and controls SREBP protein stability
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Nicotinamide (25 mM) treatment was performed for 6-20 h; as noted, this concentration is within the range of physiological effect for SIRT1 in cell culture (Rodgers et al. 2005).”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > Tissue culture
What the sources say
- Not checked — no full text of the sourcecites Rodgers et al. 2005 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“SIRT1 directly deacetylates SREBP and controls SREBP protein stability.”
§ Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP > p300 HAT assays
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
Changes in SREBP target gene expression reflect changes in SREBP transcriptional activity.
“We also found that treatment of human cell lines with SRT2183 results in significantly decreased expression of SREBP target genes in a dose-dependent manner, consistent with our model (Fig. 7D; data not shown).”
The paper relies on this without support.
Nuclear abundance of SREBP isoforms reflects their functional activity.
“We found that nicotinamide, sirtinol, and siRNA-mediated ablation of SIRT1 all increased the nuclear abundance of SREBP-1a and SREBP-2 in primary human fibroblasts (IMR-90) and cancer cells (HeLa S) (Fig. 6A,B; Supplemental Figs. 7, 8).”
The paper relies on this without support.
FASN is an SREBP target gene.
“Genetically (ob/ob) obese mice fed a high-fat diet and treated with SRT1720 daily for 2 and 4 wk exhibit significantly lower expression of the SREBP target gene FASN in the liver at 4 wk as compared with vehicle-treated mice (Fig. 7E).”
The paper relies on this without support.
Liver weight and hepatic lipid content are valid measures of hepatosteatosis.
“Importantly, ob/ob mice treated with SRT1720 for 4 wk have significantly improved hepatosteatosis, as judged by decreased liver weight and hepatic lipids (Fig. 7F; data not shown).”
The paper relies on this without support.
The ob/ob mouse high-fat diet model is relevant to human metabolic syndrome/hepatosteatosis.
“Genetically (ob/ob) obese mice fed a high-fat diet and treated with SRT1720 daily for 2 and 4 wk exhibit significantly lower expression of the SREBP target gene FASN in the liver at 4 wk as compared with vehicle-treated mice (Fig. 7E).”
The paper relies on this without support.
RNAi-mediated SIRT1 ablation is specific for SIRT1.
“We found that nicotinamide, sirtinol, and siRNA-mediated ablation of SIRT1 all increased the nuclear abundance of SREBP-1a and SREBP-2 in primary human fibroblasts (IMR-90) and cancer cells (HeLa S) (Fig. 6A,B; Supplemental Figs. 7, 8).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Sirtinol treatment duration differs between methods and figure legend
MinorThe methods specify a 20-hour treatment with 0.1 mM sirtinol, whereas the Figure 4B legend describes a 5-hour treatment at the same concentration.
“Sirtinol (0.1 mM) treatment occurred for 20 h”
“Treatment of human IMR-90 fibroblasts with the sirtuin inhibitors nicotinamide (NAM; 20 mM) or sirtinol (0.1 mM) for 5 h”
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
THE GENETICS OF CAENORHABDITIS ELEGANS
Brenner, S. (1974) · Genetics · doi:10.1093/genetics/77.1.71 · Cited by 15,220
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Self-citationSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Self-citationBrown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
Systematic functional analysis of the Caenorhabditis elegans genome using RNAi
Kamath, R. S., Fraser, A. G., Yan, D., Poulin, G. B., Durbin, R. M., Gotta, M., Kanapin, A. A., Bot, N. L., Moreno, S., Sohrmann, M., et al. (2003) · Nature · doi:10.1038/nature01278 · Cited by 3,629
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300
Self-citationNutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1042/0264-6021:3500389 · DOI
Cited by
Sorted by citations
Energy Metabolism in the Liver
Rui, L. (2014) · Comprehensive physiology · doi:10.1002/cphy.c130024 · Cited by 2,401
Sirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008
Mechanisms and regulation of cholesterol homeostasis
Luo, J., Yang, H., & Song, B.-L. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0190-7 · Cited by 1,980
Li, Y., Xu, S., Mihaylova, M. M., Zheng, B., Hou, X., Jiang, B., Park, O., Luo, Z., Lefai, É., Shyy, J. Y.-J., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.009 · Cited by 1,840
Cantó, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., Fernandez-Marcos, P. J., Yamamoto, H., Andreux, P. A., Cettour-Rose, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.022 · Cited by 1,238
SIRT1 and other sirtuins in metabolism
Chang, H.-C., & Guarente, L. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.12.001 · Cited by 1,157
MicroRNAs in metabolism and metabolic disorders
Rottiers, V., & Näär, A. M. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3313 · Cited by 1,156
Self-citationBian, X., Liu, R. R., Meng, Y., Xing, D., Xu, D., & Lu, Z. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201606 · Cited by 1,037
Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds
Bonkowski, M. S., & Sinclair, D. A. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.93 · Cited by 834
Flipping the Metabolic Switch: Understanding and Applying the Health Benefits of Fasting
Anton, S. D., Moehl, K., Donahoo, W. T., Marosi, K., Lee, S. A., Mainous, A. G., Leeuwenburgh, C., & Mattson, M. P. (2017) · Obesity · doi:10.1002/oby.22065 · Cited by 822
Sirtuin 1 and Sirtuin 3: Physiological Modulators of Metabolism
Nogueiras, R., Habegger, K. M., Chaudhary, N., Finan, B., Banks, A. S., Dietrich, M. O., Horváth, T. L., Sinclair, D. A., Pfluger, P. T., & Tschöp, M. H. (2012) · Physiological Reviews · doi:10.1152/physrev.00022.2011 · Cited by 724
Transcriptional regulation of hepatic lipogenesis
Wang, Y., Viscarra, J., Kim, S.-J., & Sul, H. S. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4074 · Cited by 646
Crosstalk between components of circadian and metabolic cycles in mammals
Asher, G., & Schibler, U. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.01.006 · Cited by 601
SIRT1 Deacetylates and Inhibits SREBP-1C Activity in Regulation of Hepatic Lipid Metabolism*
Ponugoti, B., Kim, D.-H., Xiao, Z., Smith, Z., Miao, J., Zang, M., Wu, S.-Y., Chiang, C., Veenstra, T. D., & Kemper, J. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.122978 · Cited by 553
Expanding Roles for SREBP in Metabolism
Shao, W., & Espenshade, P. J. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.002 · Cited by 525
The role of ubiquitination and deubiquitination in cancer metabolism
Sun, T., Liu, Z., & Yang, Q. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01262-x · Cited by 523
Guarente, L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100831 · Cited by 510
Sirtuins and NAD + in the Development and Treatment of Metabolic and Cardiovascular Diseases
Kane, A. E., & Sinclair, D. A. (2018) · Circulation Research · doi:10.1161/circresaha.118.312498 · Cited by 497
Calorie restriction and sirtuins revisited
Guarente, L. (2013) · Genes & Development · doi:10.1101/gad.227439.113 · Cited by 464
A Conserved SREBP-1/Phosphatidylcholine Feedback Circuit Regulates Lipogenesis in Metazoans
Walker, A. K., Jacobs, R. L., Watts, J. L., Rottiers, V., Jiang, K., Finnegan, D. M., Shioda, T., Hansen, M., Yang, F., Niebergall, L. J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.045 · Cited by 462
Self-citationTargeting Sirtuin 1 to Improve Metabolism: All You Need Is NAD+?
Cantó, C., & Auwerx, J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003905 · Cited by 433
He, M., Chiang, H.-H., Luo, H., Zheng, Z., Qiao, Q., Wang, L., Tan, M., Ohkubo, R., Mu, W.-C., Zhao, S., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.01.009 · Cited by 425
Are sirtuins viable targets for improving healthspan and lifespan?
Baur, J. A., Ungvari, Z. I., Minor, R. K., Couteur, D. G. L., & de Cabo, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3738 · Cited by 393
Seven sirtuins for seven deadly diseases ofaging
Morris, B. J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.525 · Cited by 386
Emerging roles of SIRT1 in fatty liver diseases
Ding, R., Bao, J., & Deng, C. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.19370 · Cited by 364
Mammalian Sirt1: insights on its biological functions
Rahman, S., & Islam, R. (2011) · Cell Communication and Signaling · doi:10.1186/1478-811x-9-11 · Cited by 362
Li, X. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms108 · Cited by 360
Self-citationSirtuins mediate mammalian metabolic responses to nutrient availability
Chalkiadaki, A., & Guarente, L. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.225 · Cited by 344
MXL-3 and HLH-30 transcriptionally link lipolysis and autophagy to nutrient availability
O’Rourke, E. J., & Ruvkun, G. (2013) · Nature Cell Biology · doi:10.1038/ncb2741 · Cited by 333
SRT1720 improves survival and healthspan of obese mice
Minor, R. K., Baur, J. A., Gomes, A. P., Ward, T. M., Csiszár, A., Mercken, E. M., Abdelmohsen, K., Shin, Y., Cantó, C., Scheibye‐Knudsen, M., et al. (2011) · Scientific Reports · doi:10.1038/srep00070 · Cited by 306
Self-citationSirtuin 1 in lipid metabolism and obesity
Schug, T. T., & Li, X. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.547211 · Cited by 295
Self-citationDNA damage response and metabolic disease
Shimizu, I., Yoshida, Y., Suda, M., & Minamino, T. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.10.008 · Cited by 286
Sirtuins in Epigenetic Regulation
Jing, H., & Lin, H. (2015) · Chemical Reviews · doi:10.1021/cr500457h · Cited by 276
Physiological and pathological roles of lipogenesis
Jeon, Y. G., Kim, Y. Y., Lee, G., & Kim, J. B. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00786-y · Cited by 276
SIRT1: recent lessons from mouse models
Herranz, D., & Serrano, M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2962 · Cited by 261
Hong, S., Moreno‐Navarrete, J. M., Wei, X., Kikukawa, Y., Tzameli, I., Prasad, D., Lee, Y., Asara, J. M., Fernández‐Real, J. M., Maratos–Flier, E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3882 · Cited by 260
Nicotinamide N -Methyltransferase: More Than a Vitamin B3 Clearance Enzyme
Pissios, P. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.02.004 · Cited by 259
Choi, S., Fu, T., Seok, S., Kim, D., Yu, E., Lee, K. W., KANG, Y. Y., Li, X., KEMPER, B. W., & Kemper, J. K. (2013) · Aging Cell · doi:10.1111/acel.12135 · Cited by 251
Self-citationObesity and aging: Molecular mechanisms and therapeutic approaches
Santos, A. L., & Sinha, S. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101268 · Cited by 249
Regulation of cholesterol homeostasis
Goedeke, L., & Fernandez-Hernando, C. F. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0857-5 · Cited by 232
Nicotinamide Riboside—The Current State of Research and Therapeutic Uses
Mehmel, M., Jovanović, N. D., & Spitz, U. P. (2020) · Nutrients · doi:10.3390/nu12061616 · Cited by 231
Su, G., Crump, D., Letcher, R. J., & Kennedy, S. W. (2014) · Environmental Science & Technology · doi:10.1021/es5039547 · Cited by 227
A SIRT1-LSD1 Corepressor Complex Regulates Notch Target Gene Expression and Development
Mulligan, P., Yang, F., Stefano, L. D., Ji, J., Ouyang, J., Nishikawa, J. L., Toiber, D., Kulkarni, M., Wang, Q., Najafi-Shoushtari, S. H., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.04.020 · Cited by 221
Self-citationElevation of JAML Promotes Diabetic Kidney Disease by Modulating Podocyte Lipid Metabolism
Fu, Y., Sun, Y., Wang, M., Hou, Y., Huang, W. C., Zhou, D., Wang, Z., Yang, S., Tang, W., Zhen, J., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.019 · Cited by 220
Sirtuins in glucose and lipid metabolism
Ye, X., Li, M., Hou, T., Gao, T., Zhu, W., & Yang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12157 · Cited by 219
Majeed, Y., Halabi, N. M., Madani, A. Y., Engelke, R., Bhagwat, A. M., Abdesselem, H., Agha, M. V., Vakayil, M., Courjaret, R. J., Goswami, N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87759-x · Cited by 220
Sirtuins and renal diseases: relationship with aging and diabetic nephropathy
Kitada, M., Kume, S., Takeda‐Watanabe, A., Kanasaki, K., & Koya, D. (2012) · Clinical Science · doi:10.1042/cs20120190 · Cited by 212
Shah, S. A., Yoon, G. H., Chung, S. S., Abid, M. N., Kim, T. H., Lee, H. Y., & Kim, M. O. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.23 · Cited by 206
Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease
de Gregorio, E., Colell, A., Morales, A., & Marı́, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113858 · Cited by 203
From sirtuin biology to human diseases: an update
Sebastián, C., Satterstrom, F. K., Haigis, M. C., & Mostoslavsky, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.402768 · Cited by 201
Self-citationMammalian Sirtuins and Energy Metabolism
Li, X., & Kazgan, N. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.575 · Cited by 196
Self-citationSirtuins in metabolism, DNA repair and cancer
Mei, Z., Zhang, X., Yi, J., Huang, J., He, J., & Tao, Y. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0461-5 · Cited by 196
Resveratrol as a calorie restriction mimetic: therapeutic implications
Chung, J. H., Manganiello, V., & Dyck, J. R. B. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.07.004 · Cited by 192
The role of sirtuins in aging and age-related diseases
Wątroba, M., & Szukiewicz, D. (2015) · Advances in Medical Sciences · doi:10.1016/j.advms.2015.09.003 · Cited by 190
Acetyl-CoA Metabolism and Histone Acetylation in the Regulation of Aging and Lifespan
Bradshaw, P. C. (2021) · Antioxidants · doi:10.3390/antiox10040572 · Cited by 189
NAD+ Controls Circadian Reprogramming through PER2 Nuclear Translocation to Counter Aging
Levine, D. C., Hong, H., Weidemann, B. J., Ramsey, K. M., Affinati, A. H., Schmidt, M. S., Cedernaes, J., Omura, C., Braun, R., Lee, C., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.010 · Cited by 184
Hepatic SREBP-2 and cholesterol biosynthesis are regulated by FoxO3 and Sirt6
Tao, R., Xiong, X., DePinho, R. A., Deng, C., & Dong, X. C. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m039339 · Cited by 183
Understanding the Function of Mammalian Sirtuins and Protein Lysine Acylation
Wang, M., & Lin, H. (2021) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-082520-125411 · Cited by 174
Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy
Xue, L., Qi, H., Zhang, H., Ding, L., Huang, Q., Zhao, D., Wu, B. J., & Li, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01510 · Cited by 172
Self-citationPoss, Z. C., Ebmeier, C. C., Odell, A. T., Tangpeerachaikul, A., Lee, T., Pelish, H. E., Shair, M. D., Dowell, R. D., Old, W. M., & Taatjes, D. J. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.030 · Cited by 170
MicroRNA-217 Promotes Ethanol-induced Fat Accumulation in Hepatocytes by Down-regulating SIRT1
Yin, H., Hu, M., Zhang, R., Shen, Z., Flatow, L., & You, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.333534 · Cited by 167
Hepatic Fatty Acid Trafficking: Multiple Forks in the Road
Mashek, D. G. (2013) · Advances in Nutrition · doi:10.3945/an.113.004648 · Cited by 167
Hepatic glucose sensing is required to preserve β cell glucose competence
Seyer, P., Vallois, D., Poitry‐Yamate, C., Schütz, F., Metref, S., Tarussio, D., Maechler, P., Staels, B., Lanz, B., Rolf Gruetter, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65538 · Cited by 165
Insulin signaling in fatty acid and fat synthesis: a transcriptional perspective
Wong, R. H.-F., & Sul, H. S. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.08.004 · Cited by 164
Hippo Signaling: Key Emerging Pathway in Cellular and Whole-Body Metabolism
Ardestani, A. D., Lupše, B., & Maedler, K. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.04.006 · Cited by 161
Novel Role of the SIRT1 in Endocrine and Metabolic Diseases
Lu, C., Zhao, H., Liu, Y., Yang, Z., Yao, H., Liu, T., Gou, T., Wang, L., Zhang, J., Tian, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.78654 · Cited by 160
Chen, Z. B., Wen, L., Martin, M., Hsu, C., Fang, L., Lin, F.-M., Lin, T.-Y., Geary, M. J., Geary, G. G., Zhao, Y., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.013675 · Cited by 158
Regulation of unfolded protein response modulator XBP1s by acetylation and deacetylation
Wang, F., Chen, Y., & Ouyang, H. (2010) · Biochemical Journal · doi:10.1042/bj20101293 · Cited by 158
Sirtuins and Insulin Resistance
Zhou, S., Tang, X., & Chen, H. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00748 · Cited by 155
Fu, T., Choi, S., Kim, D.-H., Seok, S., Suino-Powell, K. M., Xu, H. E., & Kemper, J. K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205951109 · Cited by 150
Sirtuins Are Evolutionarily Conserved Viral Restriction Factors
Koyuncu, E., Budayeva, H. G., Miteva, Y., Ricci, D. P., Silhavy, T. J., Shenk, T. E., & Cristea, I. M. (2014) · mBio · doi:10.1128/mbio.02249-14 · Cited by 148
Du, C., Lin, X., Xu, W., Zheng, F., Cai, J., Yang, J., Cui, Q., Tang, C., Cai, J., Xu, G., et al. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7195 · Cited by 147
Lee, D.-Y., Jeong, D., Son, H. G., Yamaoka, Y., Kim, H., Seo, K., Khan, A. A., Roh, T., Moon, D. W., Lee, Y., et al. (2015) · Genes & Development · doi:10.1101/gad.266304.115 · Cited by 143
COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm
Lee, W., Ahn, J. H., Park, H. H., Kim, H. N., Kim, H., Yoo, Y., Shin, H., Hong, K. S., Jang, J. G., Park, C. G., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00292-7 · Cited by 141
Roberti, A., Fernández, A. F., & Fraga, M. F. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101165 · Cited by 141
SCAP/SREBPs are Central Players in Lipid Metabolism and Novel Metabolic Targets in Cancer Therapy
Cheng, X., Li, J., & Guo, D. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180523104541 · Cited by 139
Cellular and molecular effects of sirtuins in health and disease
Horio, Y., Hayashi, T., Kuno, A., & Kunimoto, R. (2011) · Clinical Science · doi:10.1042/cs20100587 · Cited by 138
Tao, R., Wei, D., Gao, H., Liu, Y., DePinho, R. A., & Dong, X. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.201061 · Cited by 138
Sirtuins, metabolism, and DNA repair
Choi, J.-E., & Mostoslavsky, R. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2014.05.005 · Cited by 136
Self-citationResveratrol and obesity: can resveratrol relieve metabolic disturbances?
de Ligt, M., Timmers, S., & Schrauwen, P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.012 · Cited by 135
Wu, T., Liu, Y., Fu, Y., Liu, X., & Zhou, X.-H. (2014) · PubMed · Cited by 134
Sirtuin 1 signaling and alcoholic fatty liver disease.
You, M., Jogasuria, A. P., Taylor, C., & Wu, J. (2015) · PubMed Central · doi:10.3978/j.issn.2304-3881.2014.12.06 · Cited by 131
A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity
Kim, D., Xiao, Z., Kwon, S., Sun, X., Ryerson, D., Tkac, D., Ma, P., Wu, S., Chiang, C., Zhou, E., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201489527 · Cited by 126
de Toledo, F. W., Grundler, F., Sirtori, C. R., & Ruscica, M. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1770849 · Cited by 125
Alphonse, P. A. S., & Jones, P. J. H. (2015) · Lipids · doi:10.1007/s11745-015-4096-7 · Cited by 124
MicroRNAs in Metabolism and Metabolic DiseasesPreprint
Rottiers, V., Najafi-Shoushtari, S. H., Kristo, F., Gurumurthy, S., Zhong, L., Li, Y., Cohen, D. E., Gerszten, R. E., Bardeesy, N. M., Mostoslavsky, R., et al. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.011049 · Cited by 126
Self-citationAdiponectin triggers breast cancer cell death via fatty acid metabolic reprogramming
Pham, D., & Park, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02223-y · Cited by 123
SIRT1 metabolic actions: Integrating recent advances from mouse models
Boutant, M., & Cantó, C. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.10.006 · Cited by 122
Role of Caspase-1 in the Pathogenesis of Inflammatory-Associated Chronic Noncommunicable Diseases
Molla, M. D., Akalu, Y., Geto, Z., Dagnew, B., Ayelign, B., & Shibabaw, T. (2020) · Journal of Inflammation Research · doi:10.2147/jir.s277457 · Cited by 119
Zhang, D., Tong, X., VanDommelen, K., Gupta, N., Stamper, K., Brady, G. F., Meng, Z., Lin, J. D., Rui, L., Omary, M. B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89934 · Cited by 117
Sirtuins, resveratrol and the intertwining cellular pathways connecting them
Ungurianu, A., Zanfirescu, A., & Margina, D. M. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101936 · Cited by 114
The role of SIRT1 in ocular aging
Mimura, T., Kaji, Y., Noma, H., Funatsu, H., & Okamoto, S. (2013) · Experimental Eye Research · doi:10.1016/j.exer.2013.07.017 · Cited by 114
The roles of sirtuins family in cell metabolism during tumor development
Zhu, S., Dong, Z., Ke, X., Hou, J., Zhao, E., Zhang, K., Wang, F., Yang, L., Xiang, Z., & Cui, H. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.11.003 · Cited by 113
Kim, K. E., Jung, Y., Min, S., Nam, M., Heo, R. W., Jeon, B. T., Song, D. H., Yi, C., Jeong, E. A., Kim, H., et al. (2016) · Scientific Reports · doi:10.1038/srep30111 · Cited by 112
Diverse Roles of SIRT1 in Cancer Biology and Lipid Metabolism
Simmons, G. E., Jr., Pruitt, W. M., & Pruitt, K. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16010950 · Cited by 111
Borengasser, S. J., Lau, F., Kang, P., Blackburn, M. L., Ronis, M. J. J., Badger, T. M., & Shankar, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024068 · Cited by 111
NAD+ as a Signaling Molecule Modulating MetabolismPreprint
Canto, C., & Auwerx, J. H. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2012.76.010439 · Cited by 111
Sirtuin-1 regulation of mammalian metabolism
Gillum, M. P., Erion, D. M., & Shulman, G. I. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.005 · Cited by 110
Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis
Novák, J., Olejníčková, V., Tkáčová, N., & Santulli, G. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-22380-3_5 · Cited by 95
Pro-apoptotic miRNA-128-2 modulates ABCA1, ABCG1 and RXRα expression and cholesterol homeostasis
Adlakha, Y. K., Khanna, S., Singh, R., Singh, V. P., Agrawal, A., & Saini, N. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.301 · Cited by 109
Metadata
- Authors
- Walker, A. K., Yang, F., Jiang, K., Ji, J.-Y., Watts, J. L., Purushotham, A., Boss, O., Hirsch, M. L., Ribich, S., Smith, J. J., Israelian, K., Westphal, C. H., Rodgers, J. T., Shioda, T., Elson, S. L., Mulligan, P., Najafi-Shoushtari, H., Black, J. C., Thakur, J. K., Kadyk, L. C., Whetstine, J. R., Mostoslavsky, R., Puigserver, P., Li, X., Dyson, N. J., Hart, A. C., & Näär, A. M.
- Affiliations
- Massachusetts General Hospital (US)
- Harvard University (US)
- Washington State University (US)
- National Institutes of Health (US)
- Exelixis (United States) (US)
- Brown University (US)
- ORCID
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2010-07-01
- Volume
- 24
- Issue
- 13
- Pages
- 1403-1417
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC2895199
- OpenAlex
- W2127088568
- Cited by
- 357
- References
- 74
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 17 · 2023: 24 · 2022: 12 · 2021: 26 · 2020: 30 · 2019: 19 · 2018: 16 · 2017: 15 · 2016: 24 · 2015: 24 · 2014: 36 · 2013: 33 · 2012: 28
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of General Medical Sciences (R01GM093072, R01GM053203, R01GM071449)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK074114, R01DK088190, R01DK084352, R01DK07833)
- National Center for Research Resources
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- SIRT1, SREBP, fasting, lipid homeostasis, cholesterol homeostasis, protein deacetylation, ubiquitination, protein stability, hepatic lipid synthesis, hepatic steatosis, fat deposition, evolutionary conservation, SIRT1 activators, metabolic syndrome, atherosclerosis
- MeSH terms
- Acetylation, Animals, Benzamides, Cell Line, Cholesterol, Fasting, HeLa Cells, Heterocyclic Compounds, 4 or More Rings, Humans, Lipids, Naphthols, Niacinamide, Down-Regulation, Caenorhabditis elegans, Sirtuins, Mice, Sterol Regulatory Element Binding Protein 1, Sterol Regulatory Element Binding Protein 2, Protein Stability, Sirtuin 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
